Ontology highlight
ABSTRACT:
SUBMITTER: Colca JR
PROVIDER: S-EPMC3604641 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
Colca J R JR VanderLugt J T JT Adams W J WJ Shashlo A A McDonald W G WG Liang J J Zhou R R Orloff D G DG
Clinical pharmacology and therapeutics 20130118 4
It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator-activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week protocol with 50, 100, or 150 mg of MSDC-0160 (an mTOT modulator), 45 mg pioglitazone HCl (a PPAR-γ agonist), or a placebo. The two active treatments lowered fasting glucose levels to ...[more]